Akèy › Neoplazmi myeloproliferatif › Massachusetts › Boston
Etid klinik pou Neoplazmi myeloproliferatif nan Boston, MA
14 etid pou Neoplazmi myeloproliferatif ap chèche patisipan nan sit nan ak bò kote Boston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Ap rekriteFaz 2
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Ap rekriteFaz 2
- Dana-Farber Cancer Institute, Boston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Ap rekriteFaz 1/2
- Dana-Farber Cancer Institute, Boston
Project: Every Child for Younger Patients With Cancer
Ap rekriteEtid obsèvasyon
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis
Ap rekriteFaz 1
- Mass General Brigham, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Ap rekriteFaz 1Volontè an sante akeyi
- Brigham and Women's Hospital, Boston
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Ap rekriteFaz 1
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Ap rekriteFaz 1
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Ap rekriteFaz 1
- Dana Farber Cancer Institute, Boston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Ap rekriteFaz 2
- Dana-Farber Cancer Institute, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Ap rekriteFaz 2Volontè an sante akeyi
- DFCI/BWH Brigham and Women's Hospital, Boston
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
Ap rekrite
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
Etid Neoplazmi myeloproliferatif nan lòt vil
- Houston, TX16 etid
- New York City, NY15 etid
- Milwaukee, WI10 etid
- Miami, FL10 etid
- Chicago, IL9 etid
- Durham, NC9 etid
- Baldwin Park, CA9 etid
- Seattle, WA9 etid
- Atlanta, GA8 etid
- Tampa, FL8 etid
- Birmingham, AL8 etid
- Columbus, OH8 etid
Lòt etid nan Boston
- Kansè nan tete111 etid
- Kansè Poumon ki pa ti selil90 etid
- Kansè (tout kalite)86 etid
- Kansè kolorektal63 etid
- Kansè Metastatik63 etid
- Kansè poumon62 etid
- Kansè ovè61 etid
- Kansè pwostat59 etid
- Depresyon52 etid
- Kansè Endomèt50 etid
- Ensifizyans kadyak44 etid
- Leksemi mieloïd egi44 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.